Drug profile · INN
miglustat
MIGLUSTAT DIPHARMA
miglustat (MIGLUSTAT DIPHARMA) is a ceramide glucosyltransferase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — miglustat
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
miglustat (MIGLUSTAT DIPHARMA) is a ceramide glucosyltransferase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Ceramide glucosyltransferase inhibitor
Primary target: Ceramide glucosyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is miglustat?
miglustat (MIGLUSTAT DIPHARMA) is a ceramide glucosyltransferase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for miglustat?
MIGLUSTAT DIPHARMA is a marketed brand name for miglustat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of miglustat?
miglustat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.